Hostname: page-component-8448b6f56d-gtxcr Total loading time: 0 Render date: 2024-04-24T23:00:58.069Z Has data issue: false hasContentIssue false
  • English
  • Français

A double-blind randomised comparative trial of amisulpride versus olanzapine for 2 months in the treatment of subjects with schizophrenia and comorbid depression

Published online by Cambridge University Press:  16 April 2020

J.-M. Vanelle  and
S. Douki
J.-M. Vanelle*
Affiliation:
Service de psychiatrie, hôpital Saint-Jacques, 85, rue Saint-Jacques, 44200Nantes, France
S. Douki
Affiliation:
Hôpital Razi, La Manouba, Tunisia
*
*Corresponding author. E-mail address: jean-marie.vanelle@chu-nantes.fr (J.-M. Vanelle).
Get access

Abstract

Purpose

To compare the efficacy and safety of amisulpride and olanzapine in subjects with schizophrenia and comorbid depression in a randomised double-blind trial.

Patients

Eighty-five adult patients fulfilling DSM-IV criteria for schizophrenia and presenting a depressive episode were randomised to amisulpride (200–600 mg/day) or olanzapine (5–15 mg/day) for 8 weeks. Primary efficacy variables were change in Calgary Depression Scale (CDS) score and Clinical Global Impression (CGI) of Change. Safety was monitored by adverse event reporting and determination of extrapyramidal function and metabolic variables.

Results

The mean change from baseline of CDS score was –6.84 in the amisulpride group and –7.36 in the olanzapine group. 65.9% and 61.5% of subjects, respectively, were considered “much” or “very much” improved. No significant inter-group difference in effect size was observed. The frequency of adverse events was low and emergence of extrapyramidal symptoms was not seen. Four patients in the olanzapine group developed abnormal triglyceride levels. Mean weight gain was 1.45 and 0.5 kg, respectively, in the olanzapine and amisulpride groups.

Conclusion

Amisulpride and olanzapine are effective in patients with schizophrenia and comorbid depression. Tolerance of both drugs was acceptable, although use of olanzapine was associated with a trend toward greater metabolic side-effects [19].

Keywords

AmisulprideOlanzapineSchizophreniaDepressionRandomised clinical trial
Type
Original article
Information
European Psychiatry , Volume 21 , Issue 8 , December 2006 , pp. 523 - 530
Copyright
Copyright © Elsevier Masson SAS 2006

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Addington, D., Addington, J., Maticka-Tyndale, E.Assessing depression in schizophrenia. The Calgary Depression Scale Br. J. Psychiatry 163(Suppl 22)1992 39–44.CrossRefGoogle Scholar
Addington, D., Addington, J., Maticka-Tyndale, E., Joyce, J.Reliability and validity of a depression rating scale for schizophrenics Schizophr. Res. 1993; 6:201–208.CrossRefGoogle Scholar
Allison, D.B., Casey, D.E.Antipsychotic-induced weight gain: a review of the literature J. Clin. Psychiatry 62(Suppl 7)2001 22–31.Google ScholarPubMed
American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed Washington, DC, USA: American Psychiatric Association; 1994.Google Scholar
Barnes, T.R.E.A rating scale for akathisia Br. J. Psychiatry 1984; 154:672–673.CrossRefGoogle Scholar
Bell, M., Milstein, R., Beam-Gould, J., Cicchetti, D.The Positive and Negative Syndrome Scale and the Brief Psychiatric Rating Scale. Reliability, comparability and predictive validity J. Nerv. Ment. Dis. 1992; 180:723–728.CrossRefGoogle ScholarPubMed
Boyer, P., Lecrubier, Y., Stalla-Bourdillon, A., Fleurot, O.Amisulpride versus amineptine and placebo for the treatment of dysthymia Neuropsychobiology 1999; 39:25–32.CrossRefGoogle ScholarPubMed
Collaborative Working Group on clinical trial evaluations. Atypical antipsychotics for treatment of depression in schizophrenia and affective disorders J. Clin. Psychiatry 59(Suppl 12)1998 41–45.Google Scholar
Coulouvrat, C., Dondey-Nouvel, L.Safety of amisulpride (Solian): a review of 11 clinical studies Int. Clin. Psychopharmacol. 1999; 14:209–218.CrossRefGoogle ScholarPubMed
Duggan, L., Fenton, M., Rathbone, J., Dardennes, R.M., El-Dosoky, A., Indran, S.Olanzapine for schizophrenia Cochrane Database Syst. Rev. 2003: (1) [CD001359]Google Scholar
Kay, S.R., Fiszbzin, A., Opler, L.A.The Positive and Negative Syndrome Scale for schizophrenia Schizophr. Bull. 1987; 3:261–276.CrossRefGoogle Scholar
Koro, C.E., Fedder, D.O., L’Italien, G.J., Weiss, S.S., Magder, L.S., Kreyenbuhl, J.et al.An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic subjects Arch. Gen. Psychiatry 2002; 59:1021–1026.CrossRefGoogle Scholar
Koro, C.E., Fedder, D.O., L’Italien, G.J., Weiss, SS., Magder, L.S., Kreyenbuhl, J.et al.Assessment of independent effect of olanzapine and risperidone on risk of diabetes among subjects with schizophrenia: population based nested case-control study BMJ 2002; 325:243–248.CrossRefGoogle Scholar
Lecrubier, Y., Boyer, P., Turjanski, S., Rein, W.Amisulpride versus imiprimine and placebo in dysthymia and major depression. Amisulpride Study Group J. Affect. Disord. 1997; 43:95–103.CrossRefGoogle Scholar
Leucht, S., Pitschel-Walz, G., Engel, R.R., Kissling, W.Amisulpride, an unusual “atypical” antipsychotic: a meta-analysis of randomized controlled trials Am. J. Psychiatry 2002; 159:180–190.CrossRefGoogle ScholarPubMed
Martin, S., Löo, H., Peuskens, J., Thirumalai, S., Giudicelli, A., Fleurot, O.A double-blind randomised comparative trial of amisulpride versus olanzapine in the treatment of schizophrenia: short-term results at two months Curr. Med. Res. Opin. 2002; 18:355–362.CrossRefGoogle ScholarPubMed
Meltzer, H.Y.Treatment of suicidality in schizophrenia Ann. N. Y. Acad. Sci. 2001; 932:44–60.CrossRefGoogle Scholar
Meltzer, H.Y., Alphs, L., Green, A.I., Altamura, A.C., Anand, R., Bertoldi, A.et al.Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT) Arch. Gen. Psychiatry 2003; 60:82–91.CrossRefGoogle Scholar
Möller, H.J., Boyer, P., Fleurot, O., Rein, W.Improvement of acute exacerbations of schizophrenia with amisulpride: a comparison with haloperidol. PROD-ASLP Study Group Psychopharmacology (Berl.) 1997; 132:396–401.Google ScholarPubMed
Mortimer, A., Martin, S., Loo, H.Peuskens J for the SOLIANOL Study Group A double-blind randomised comparative trial of amisulpride versus olanzapine for six months in the treatment of schizophrenia Int. Clin. Psychopharmacol. 2004; 19:63–69.CrossRefGoogle Scholar
National Institute of Mental Health. CGI, Abnormal involuntary Movement Scale. Guy, W., ECDEU assessment manual of psychopharmacology review Rockville, USA: NIMH; 1976. 534–537.Google Scholar
National Institute of Mental Health. CGI, Clinical Global Impression. Guy, W., ECDEU assessment manual of psychopharmacology review Rockville, USA: NIMH; 1976. 217–222.Google Scholar
Overall, J.E., Gorham, D.R.The Brief Psychiatric Rating Scale Psychol. Rep. 1962; 10:799–812.CrossRefGoogle Scholar
Papp, M., Wieronska, J.Antidepressant-like activity of amisulpride in two animal models of depression J. Psychopharmacol. 2000; 14:46–52.CrossRefGoogle ScholarPubMed
Peuskens, J., Möller, H.J., Peuch, A.Amisulpride improves depressive symptoms in acute exacerbations of schizophrenia: comparison with haloperidol and risperidone Eur. Neuropsychopharmacol. 2002; 12:305–310.CrossRefGoogle ScholarPubMed
Peuskens, J., van Baelen, B., de Smedt, C., Lemmens, P.Effects of risperidone on affective symptoms with schizophrenia Int. Clin. Psychopharmacol. 2000; 15:343–349.CrossRefGoogle ScholarPubMed
Ravizza, L.Amisulpride in medium-term treatment of dysthymia: a six-month, double-blind safety study versus amitriptyline. AMILONG investigators J. Psychopharmacol. 1999; 13:248–254.CrossRefGoogle ScholarPubMed
Schoemaker, H., Claustre, Y., Fage, D., Rouquier, L., Chergui, K., Curet, O.et al.Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity J. Pharmacol. Exp. Ther. 1997; 280:83–97.Google ScholarPubMed
Simpson, G., Angus, J.A.A rating scale for extrapyramidal symptoms Acta Psychiatr. Scand. 45(Suppl 42)1970 11–19.CrossRefGoogle Scholar
Siris, S.G.Depression in schizophrenia: perspective in the era of “atypical” antipsychotic agents Am. J. Psychiatry 2000; 157:1379–1389.CrossRefGoogle ScholarPubMed
Tollefson, G.D., Anderson, S.W.Should we consider mood disturbance in schizophrenia as an important determinant of quality of life? J. Clin. Psychiatr. 60(Suppl 5)1999 23–29.Google ScholarPubMed
Tollefson, G.D., Sanger, T.M., Beasley, C.M., Tran, P.V.A double-blind comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia Biol. Psychiatry 1998; 43:803–810.CrossRefGoogle ScholarPubMed
Tran, P.V., Dellva, M.A., Tollefson, G.D., Beasley, C.M. Jr, Potvin, J.H., Kiesler, G.M.Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in acute treatment of schizophrenia J. Clin. Psych. 58(Suppl 10)1997 205–211.CrossRefGoogle ScholarPubMed
Submit a response

Comments

No Comments have been published for this article.